他汀类药物治疗抑郁症的疗效及安全性的Meta分析  

The efficacy and safety of statins for major depressive disorder:a Meta-analysis

作　　者：叶芬 燕银枝 戚敏恒 郑伟 YE Fen;YAN Yin-zhi;QI Min-heng(Mental Hospital of Guangzhou Givil Administration,Guangzhou 510430,China)

机构地区：[1]广州市民政局精神病院,510430 [2]广州市惠爱医院,510430

出　　处：《中国实用医药》2021年第20期149-152,共4页China Practical Medicine

摘　　要：目的采用系统评价和Meta分析的方法评估他汀类药物对抑郁症(MDD)的疗效和安全性。方法计算机检索PudMed、Embase、Cochrane图书馆、中国知网、万方数据库等数据库发表的有关他汀类药物用于治疗MDD患者的随机对照试验(RCTs)研究,主要结局指标为汉密尔顿抑郁量表(HDRS)评分的变化,次要结局指标为不良反应发生率。用Cochrane协作网研究偏倚风险评价工具评估研究质量,使用RevMan5.3软件进行数据分析。结果最终纳入5篇RCTs,共288例患者。Meta分析显示:与对照组相比,他汀类药物组对MDD改善明显,[标准化均数差(SMD)=-0.76,95%CI=(-1.00,-0.52),P<0.001],胆固醇和甘油三酯明显下降,差异有统计学意义(P<0.05)。研究显示组间不良反应差异率无统计学意义(P>0.05)。结论他汀类药物能增效改善MDD,但不能起到快速抗抑郁的作用,安全性良好。Objective To evaluate the efficacy and safety of statins for major depressive disorder(MDD)by systematic evaluation and Meta-analysis.Methods Pudmed,Embase,Cochrane,CNKI,Wanfang database were searched for randomized controlled studies(RCTs)of statins as an adjuvant therapy to MDD patients.The main outcomes were the change of Hamilton depression rating scale(HDRS)score,secondary outcomes were the incidence of adverse events.Bias risk assessment tool of Cochrane collaboration was used to assess research quality,and the data was analyzed with RevMan5.3 software.Results 5 RCTs included 288 participants with MDD.Meta-analysis showed that compared with the control group,statins improved MDD significantly[standardized mean difference(SMD)=-0.76,95%CI=(-1.00,-0.52),P<0.001],cholesterol and triglycerides decreased significantly,and the difference was statistically significant(P<0.05).There was no significantly significant difference in the incidence of adverse events between groups(P>0.05).Conclusion:Statins can effectively improve MDD with high safety,but can not play a role in the rapid anti-depression.

关 键 词：他汀 抑郁 随机 安慰剂 

分 类 号：R749.4[医药卫生—神经病学与精神病学]